1 / 19

Integrating Research and Clinical Practice

Integrating Research and Clinical Practice. Jim Koeller, M.S. Professor University of Texas at Austin & the Health Science Center, San Antonio, USA. Learning Objectives. Describe how research impacts clinical practice List 3 different types of clinical research

kele
Download Presentation

Integrating Research and Clinical Practice

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Integrating Research and Clinical Practice Jim Koeller, M.S. Professor University of Texas at Austin & the Health Science Center, San Antonio, USA

  2. Learning Objectives • Describe how research impacts clinical practice • List 3 different types of clinical research • Describe 2 research areas that can be applied to clinical practice • Give 2 examples of research that can be directly applied to daily practice • Describe 2 ways to take clinical practice and create a project or publication

  3. Your ‘Scope’ of Clinical Practice • What are your daily functions as an ‘oncology pharmacist’? • Do you directly participate in a patient environment, or is it more indirect? • Are you involved in direct patient care? • Are you involved in chemotherapy/drug preparation? • Are you involved more in dispensing functions? • Do you participate in any type of drug research?

  4. How Does Research Impact Clinical Practice? • Evidence-based clinical practice should become a standard of care • Having clinical decisions driven by clinical trials data • What types of studies provide ‘adequate’ data to base daily treatment on? • Guidelines driven care (evidence-based) • In the UK it may be NICE • In the US it may be NCCN

  5. Types of Research • Phase I - Initial human testing focusing on dosing (MTD) and toxicity • Phase II - human testing focusing on efficacy (response rates) and toxicity (randomized & blinded) • Phase III - Larger, comparative, randomized, blinded testing looking at efficacy in general use (many times compared to placebo) • Disease/Progression-free survival; overall survival

  6. Basing Oncology Practice on Research • Oncology clinical practice changes quickly • New ‘data’ is available all the time that changes how to utilize anti-cancer agents and approaches to disease treatment • To stay on the ‘cutting edge’ of clinical practice, one my stay abreast of the latest clinical research data • What types of research can be applied to your practice setting?

  7. Basing Oncology Pharmacy Practice on Research • Drug preparation and administration • Stability • Compatibility • Appropriate drug use • Keeping abreast of new drugs (regimens) and new indications • Increasing number of oral anti-cancer agents • Drug toxicity/management • Supportive care • Pharmacoeconomics • Pharmacogenomics

  8. Examples • Vascular Endothial Growth Factor (VEGF) inhibitor-induced hypertension • Monoclonal AB’s ~ Bevacizumab • Overall - up to 68% (gr 3/4 ~ 8 - 18%) • TKI’s ~ sunitinib, sorafenib • Overall - up to 43% (gr 3/4 ~ 2 - 20 %) • Can apply JNC VII guidelines • 1st line ~ thiazide diuretics • 2nd line ~ ACE-I or ARB’s • First-line if renal dysfunction/proteinuria

  9. VEGF-Induced Hypertension(Pharmacy Applying the Research Data) • Create monitoring guidelines • BP monitoring Q 2 wk, then wkly if HTN • Urine protein monitoring (same as BP) • Monitor for 3 months after tx stops • Create Guidelines for Treatment • Grade 1 ~ continue bev, continue monitoring • Grade 2 ~ stop bev, start drug tx, want <160/100 • Grade 3 ~ stop until HTN under control, combination therapy may be necessary

  10. Examples • Epidermal Growth Factor Receptor (EGFR) inhibitor/TKI- induced rash • Monoclonal AB’s ~ 40 - 85% (mild to moderate) • Cetuximab, panitumumab • TKI’s ~ 8 - 16% (mild to moderate) • Erlotinib, Gefitinib, Imatinib • See class effects: (epidermis affected) • Acneiform - acne-like rash most common • Also see dry skin, fissures, nail alterations • Rash appears to correlate with efficacy

  11. EGFR/TKI- Induced Rash(Pharmacy Applying the Research Data) • Pharmacy-Directed Treatment Guidelines • Grade 1 ~ Topical hydrocortisone 1.0/2.5% • Clindamycin 1.0/2.0% • Metronidazole 1% • Salicylic acid • Grade 2 ~ Above topical’s + • Oral minocycline/doxycycline 100mg qd/bid • Grade 3 ~ Add wet compresses • Higher dose oral tetracycline • Steroid dose pack

  12. ExamplesPharmacy-Directed Pharmacogenomic monitoring • Tamoxifen and CYP2D6 Inhibitors • Tamoxifen is metabolized into its active for by CYP2D6 • Inhibitors of CYP2D6 can decrease the conversion of tamoxifen to its active form • Woman who have a reduced-function CYP2D6 polymorphism and are poor metabolizers have lower levels of the active form (< 10% population) • Examples of CYP2D6 inhibitors • Selective serotonin reuptake inhibitors (SSRI’s) • Fluoxetine, paroxetine, sertraline (moderate inhibitors) • Can cause a 50 - 80% decrease in AUC levels of substrate drug • Weaker inhibitors ~ Venlafaxine, citalopram, fluvoxamine • Other moderate inhibitors: fluconazole, bupropion

  13. ExamplesPharmacy-Directed Pharmacogenomic monitoring • Current retrospective data suggests a 2 fold increase in relapse • Until controlled confirmatory studies can be done, it would be prudent to carefully monitor the drug therapy of women taking tamoxifen • In the future may need to test women on tamoxifen for the CYP2D6 polymorphism, however some way we should be testing all women who are to be treated with tamoxifen now… • May help identify women who should be on an alternative hormonal agent • An approved AmpliChip to test for CYP2D6 is available now in US

  14. Example • Biomarker Monitoring: • KRAS gene monitoring in colorectal cancer • In mutant KRAS tumors the protein is ‘turned on’ rendering cetuximab/panitumumab inhibition much less effective • 40% of pts have the mutant gene ~ will not respond to expensive therapy • But for the 60% with the wild-type gene, a higher response and overall survival is seen • OS ~ 9.4 mo. vs. 4.8 mo. • Pharmacy can help create the guidelines for the biomarker monitoring and drug management

  15. ExamplePharmacy-Directed Pharmacogenomic Monitoring • UGT1A1 monitoring in Irinotecan-treated patients • UGT1A1 necessary to convert irinotecan to SN 38 metabolite • UGT1A1 polymorphism is rare familial or an autosomal dominant (Gilbert’s syndrome ) alteration ~ +/- 10 - 17% • More common in hispanic/african-americans • Genotype predictor of Irinotecan toxicity which is dose-related (diarrhea) • <150mg/m2 - RR 1.8; 150 - 250mg/m2 - RR 3.2 >250 mg/m2 - RR 28

  16. ExamplePharmacy-Directed Pharmacogenomic Monitoring • Pharmacy Guidelines for UGT1A1 monitoring • <150mg/m2 ~ normal dose/no testing • 150 - 250mg/m2 ~ If 3-fold increase risk of toxicity is enough to change regimen ~ then test • >250mg/m2 ~ test/give 75% normal dose

  17. Example • Pharmacoeconomics • The UK has the National Institute for Health and Clinical Excellence (NICE) which evaluates the cost-effectiveness of cancer agents… • It issues Final Appraisal Determinations (FAD’s) • QALY, not to exceed 30,000 pounds, is considered std. • Determines if a therapy is worth the expense of the National Health Service (NHS) • This spring lenalidomide (Revlimid) plus dex was approved by NICE for use as third-line treatment in multiple myeloma (deemed cost-effective) • Also this spring, lapatinib (breast cancer) and sutent (GI, in addition to previous renal) were denied

  18. Turning Clinical Practice Into ResearchorPathways to Publication • Making research out of everyday practice…. • May be best to start with something that isn’t so intimidating! • Letter to the Editor • Case Reports • Start with an observation seen as part of you daily practice • Unusual toxicity • Drug-drug interaction • Do a literature search - see if the observation has been reported before, if it has, you now have a series to report!

  19. QUESTIONS ?

More Related